

Year 2008

(IF - Impact Factor top 500 scientific journals)

1. Ashur-Fabian O, Trakhtenbrot L, Dominissini D, Koren-Michowitz M, Nagler A, Rechavi G, Amariglio N. **The presence of a single PML-RARA isoform lacking exon 5 in FISH-negative APL samples.** *Leukemia*. 2008 Jan; 22(1):200-3. (IF 6.146)
2. Azran-Shaish I, Tabakin-Fix Y, Huleihel M, Bakhanashvili M, Aboud M. **HTLV-1 Tax-induced NF-kappaB activation is synergistically enhanced by 12-O-tetradecanoylphorbol-13-acetate: mechanism and implications for Tax oncogenicity.** *J Mol Med*. 2008 Jul; 86(7):799-814. (IF 4.820)
3. Aychek T, Miller K, Sagi-Assif O, Levy-Nissenbaum O, Israeli-Amit M, Pasmanik-Chor M, Jacob-Hirsch J, Amariglio N, Rechavi G, Witz IP. **E-selectin regulates gene expression in metastatic colorectal carcinoma cells and enhances HMGB1 release.** *Int J Cancer*. 2008 Oct 15; 123(8):1741-50. (IF 4.693)
4. Barsheshet A, Hod H, Shechter M, Sharabani-Yosef O, Rosenthal E, Barbash IM, Matetzky S, Tal R, Bentancur AG, Sela BA, Nagler A, Leor J. **The effects of external counter pulsation therapy on circulating endothelial progenitor cells in patients with angina pectoris.** *Cardiology*. 2008; 110(3):160-6. (IF 1.701)
5. Berger R, Rotem-Yehudar R, Slama G, Landes S, Kneller A, Leiba M, Koren-Michowitz M, Shimoni A, Nagler A. **Phase I Safety and Pharmacokinetic Study of CT-011, a Humanized Antibody Interacting with PD-1, in Patients with Advanced Hematologic Malignancies.** *Clin Cancer Res*. 2008 May 15; 14(10):3044-51. (IF 6.177)
6. Berger R, Avramoff A, Leiba M, Domb AJ, Laor A, Nagler A. **Cyclosporine safety and bioavailability with two second-generation softgel capsules using serum concentrations/TDM and modeling in transplant patients--a retrospective, parallel, comparative evaluation study.** *Int J Clin Pharmacol Ther*. 2008 Apr; 46(4):165-71. (IF 1.281)
7. Betts DR, Stanchesu R, Niggli FK, Cohen N, Rechavi G, Am, Trakhtenbrot L. **SKY reveals a high frequency of unbalanced translocations involving chromosome 6 in t(12;21)-positive acute ariglio N lymphoblastic leukemia.** *Leuk Res*. 2008 Jan; 32(1):39-43. (IF 2.561)
8. Bar J, Onn A. **Combined anti-proliferative and anti-angiogenic strategies for cancer.** *Expert Opin Pharmacother*. 2008 Apr; 9(5):701-15. (IF 1.733)
9. Bakhanashvili M, Gedelovich R, Grinberg S, Rahav G. **Exonucleolytic degradation of RNA by p53 protein in cytoplasm.** *J Mol Med*. 2008 Jan; 86(1):75-88. (IF 4.820)

10. Rechavi G, Rivella S. Regulation of iron absorption in hemoglobinopathies. *Curr Mol Med.* 2008 Nov; 8(7):646-62.(IF 4.624)
11. Bercovich D, Ganmore I, Scott LM, Wainreb G, Birger Y, Elimelech A, Shochat C, Cazzaniga G, Biondi A, Basso G, Cario G, Schrappe M, Stanulla M, Strehl S, Haas OA, Mann G, Binder V, Borkhardt A, Kempfski H, Trka J, Bielorai B, Avigad S, Stark B, Smith O, Dastugue N, Bourquin JP, Tal NB, Green AR, Izraeli S. Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome. *Lancet.* 2008 Oct 25; 372(9648):1484-92.(IF 28.638)
12. Erez A, Chaussepied M, Castiel A, Colaizzo-Anas T, Aplan PD, Ginsberg D, Izraeli S. The mitotic checkpoint gene, SIL is regulated by E2F1 *Int J Cancer.* 2008 Oct 1; 123(7):1721-5.(IF 4.555)
13. Golan H, Bielorai B, Grebler D, Izraeli S, Rechavi G, Toren A. Integration of a palliative and terminal care center into a comprehensive pediatric oncology department. *Pediatr Blood Cancer.* 2008 May; 50(5):949-55.(IF1.882)
14. Strehl S, Nebral K, König M, Harbott J, Strobl H, Ratei R, Struski S, Bielorai B, Lessard M, Zimmermann M, Haas OA, Izraeli S. ETV6-NCOA2: a novel fusion gene in acute leukemia associated with coexpression of T-lymphoid and myeloid markers and frequent NOTCH1 mutations. *Clin Cancer Res.* 2008 Feb 15; 14(4):977-83.(IF 6.177)
15. Bar J, Feniger-Barish R, Lukashchuk N, Shaham H, Moskovits N, Goldfinger N, Simansky D, Perlman M, Papa M, Yosepovich A, Rechavi G, Rotter V, Oren M. Cancer cells suppress p53 in adjacent fibroblasts. *Oncogene.* 2008 Dec 8. [Epub ahead of print].(IF 6.440)
16. Markel G, Seidman R, Cohen Y, Besser MJ, Sinai TC, Treves AJ, Orenstein A, Berger R, Schachter J. Dynamic expression of protective CEACAM1 on melanoma cells during specific immune attack. *Immunology.* 2008 Jun 13. [Epub ahead of print]. (IF 3.398).
17. Schallmach E, Sareli R, Besser MJ, Leipsiger S, Hardan I, Treves AJ, Nagler A, Schachter J. Collection of large-scale expanded lymphocyte cultures for adoptive immunotherapy using a COBE Spectra apheresis machine. *J Immunother.* 2008 Jul-Aug; 31(6):563-8.(IF 4.837)
18. Keshet GI, Goldstein I, Itzhaki O, Cesarkas K, Shenhav L, Yakirevitch A, Treves AJ, Schachter J, Amariglio N, Rechavi G. MDR1 expression identifies human melanoma stem cells. *Biochem Biophys Res Commun.* 2008 Apr 18; 368(4):930-6. Epub 2008 Feb 13. (IF 2.855)
19. Bladé J, Sonneveld P, San Miguel JF, Sutherland HJ, Hajek R, Nagler A, Spencer A, Robak T, Cibeira MT, Zhuang SH, Harousseau JL, Orłowski RZ, For The Doxil-Mmy-3001 Study Investigators. Pegylated Liposomal Doxorubicin plus Bortezomib in Relapsed or Refractory Multiple Myeloma: Efficacy and Safety in Patients with Renal Function Impairment. *Clin Lymphoma Myeloma.* 2008 Dec 1; 8(6):352-355.(IF 3.105)

20. Avivi I, Avraham S, Koren-Michowitz M, Zuckerman T, Aviv A, Ofran Y, Benyamini N, Nagler A, Rowe JM, Nagler RM. **Oral integrity and salivary profile in myeloma patients undergoing high-dose therapy followed by autologous SCT.** *Bone Marrow Transplant.* 2008 Nov 24. [Epub ahead of print].(IF 3.000)
21. Ruvinov E, Sharabani-Yosef O, Nagler A, Einbinder T, Feinberg MS, Holbova R, Douvdevani A, Leor J. **Transplantation of genetically engineered cardiac fibroblasts producing recombinant human erythropoietin to repair the infarcted myocardium.** *Fibrogenesis Tissue Repair.* 2008 Nov 3; 1(1):7.
22. Stelljes M, van Biezen A, Slavin S, Olavarria E, Clark RE, Nagler A, Koza V, Kienast J, Niederwieser D, de Witte T, Ruutu T. **The harvest and use of autologous back-up grafts for graft failure or severe GVHD after allogeneic hematopoietic stem cell transplantation: a survey of the European Group for Blood and Marrow Transplantation.** *Bone Marrow Transplant.* 2008 Dec ; 42(11):739-42. Epub 2008 Aug 25.(IF 3.000)
23. Genin O, Rechavi G, Nagler A, Ben-Itzhak O, Nazemi KJ, Pines M. **Myofibroblasts in pulmonary and brain metastases of alveolar soft-part sarcoma: a novel target for treatment?** *Neoplasia.* 2008 Sep; 10(9):940-8.(IF 5.674)
24. Gal H, Pandi G, Kanner AA, Ram Z, Lithwick-Yanai G, Amariglio N, Rechavi G, Givol D. **MIR-451 and Imatinib mesylate inhibit tumor growth of Glioblastoma stem cells.** *Biochem Biophys Res Commun.* 2008 Nov 7; 376(1):86-90. Epub 2008 Aug 31.(IF 2.149)
25. Rolls A, Shechter R, London A, Segev Y, Jacob-Hirsch J, Amariglio N, Rechavi G, Schwartz M. **Two faces of chondroitin sulfate proteoglycan in spinal cord repair: a role in microglia/macrophage activation.** *PLoS Med.* 2008 Aug 19; 5(8):e171.(IF 12.601)
26. Nagar M, Vernitsky H, Cohen Y, Dominissini D, Berkun Y, Rechavi G, Amariglio N, Goldstein I. **Epigenetic inheritance of DNA methylation limits activation-induced expression of FOXP3 in conventional human CD25-CD4+ T cells.** *Int Immunol.* 2008 Aug ; 20(8):1041-55. Epub 2008 Jun 20. (IF 3.290)
27. Mayo L, Jacob-Hirsch J, Amariglio N, Rechavi G, Moutin MJ, Lund FE, Stein R. **Dual role of CD38 in microglial activation and activation-induced cell death.** *J Immunol.* 2008 Jul 1;181(1):92-103.(IF 6.068)
28. Puca R, Nardinocchi L, Gal H, Rechavi G, Amariglio N, Domany E, Notterman DA, Scarsella M, Leonetti C, Sacchi A, Blandino G, Givol D, D'Orazi G. **Reversible dysfunction of wild-type p53 following homeodomain-interacting protein kinase-2 knockdown.** *Cancer Res.* 2008 May 15;68(10):3707-14.(IF 7.672)
29. Goldstein I, Simon AJ, Ben Horin S, Matzri S, Koltakov A, Langevitz P, Rechavi G, Amariglio N, Bank I. **Synovial VLA-1+ T cells display an oligoclonal and partly distinct repertoire in rheumatoid and psoriatic arthritis.** *Clin Immunol.* 2008 Jul; 128(1):75-84. Epub 2008 May 5. (IF 2.561)

30. Meirow D, Hardan I, Dor J, Fridman E, Elizur S, Ra'anani H, Slyusarevsky E, Amariglio N, Schiff E, Rechavi G, Nagler A, Ben Yehuda D. **Searching for evidence of disease and malignant cell contamination in ovarian tissue stored from hematologic cancer patients.** *Hum Reprod.* 2008 May; 23(5):1007-13. Epub 2008 Mar 15 .(IF 3.769)
31. Gielchinsky Y, Bogoch Y, Rechavi G, Jacob-Hirsch J, Amariglio N, Shveiky D, Linial M, Laufer N. **Gene expression in women conceiving spontaneously over the age of 45 years.** *Fertil Steril.* 2008 Jun; 89(6):1641-50. Epub 2007 Dec 2 . (IF 3.168)
32. Haberman Y, Amariglio N, Rechavi G, Eisenberg E. **Trinucleotide repeats are prevalent among cancer-related genes.** *Trends Genet.* 2008 Jan; 24(1):14-8. Epub 2007 Dec 4 .(IF 9.729)
33. Galanti G, Fisher T, Kventsel I, Shoham J, Gallily R, Mechoulam R, Lavie G, Amariglio N, Rechavi G, Toren A. **Delta 9-tetrahydrocannabinol inhibits cell cycle progression by** *Acta Oncol.* 2008; 47(6):1062-70.(IF 2.274)
34. Bar J, Yerushalmi R, Shapira-Frummer R, Kutchuk I, Sulkes A, Gutman H, Catane R, Schachter J. **Concurrent chemobiotherapy with cisplatin, dacarbazine, decrescendo interleukin-2 and interferon alpha2b in patients with metastatic melanoma.** *Oncol Rep.* 2008 Dec; 20(6):1533-8.(IF 1.597)
35. Soudry E, Gutman H, Feinmesser M, Gutman R, Schachter J. **"Gloves-and-socks" melanoma: does histology make a difference?** *Dermatol Surg.* 2008 Oct; 34(10):1372-8. Epub 2008 Jul 2.(IF 1.769)
36. Dekel B, Metsuyanin S, Garcia AM, Quintero C, Sanchez MJ, Izraeli S. **Organ-injury-induced reactivation of hemangioblastic precursor cells.** *Leukemia.* 2008 Jan; 22(1):103-13. Epub 2007 Sep 27.(IF 6.146)
37. Forestier E, Izraeli S, Beverloo B, Haas O, Pession A, Michalová K, Stark B, Harrison CJ, Teigler-Schlegel A, Johansson B. **Cytogenetic features of acute lymphoblastic and myeloid leukemias in pediatric patients with Down syndrome: an iBFM-SG study.** *Blood.* 2008 Feb 1; 111(3):1575-83. Epub 2007 Oct 30. (IF 10.370)
38. Ron-Harel N, Segev Y, Lewitus GM, Cardon M, Ziv Y, Netanel D, Jacob-Hirsch J, Amariglio N, Rechavi G, Domany E, Schwartz M. **Age-dependent spatial memory loss can be partially restored by immune activation.** *Rejuvenation Res.* 2008 Oct; 11(5):903-13.(IF 4.728)
39. Tavor S, Eisenbach M, Jacob-Hirsch J, Golan T, Petit I, Benzion K, Kay S, Baron S, Amariglio N, Deutsch V, Naparstek E, Rechavi G. **The CXCR4 antagonist AMD3100 impairs survival of human AML cells and induces their differentiation.** *Leukemia.* 2008 Dec; 22(12):2151-5158. (IF 6.924)
40. Frumkin D, Wasserstrom A, Itzkovitz S, Stern T, Harmelin A, Eilam R, Rechavi G, Shapiro E. **Cell lineage analysis of a mouse tumor.** *Cancer Res.* 2008 Jul 15; 68(14):5924-31.(IF 7.672)

41. Golan N, Adamsky K, Kartvelishvily E, Brockschnieder D, Möbius W, Spiegel I, Roth AD, Thomson CE, Rechavi G, Peles E. **Identification of Tmem10/Opalin as an oligodendrocyte enriched gene using expression profiling combined with genetic cell ablation.** *Glia*. 2008 Aug 15; 56(11):1176-86.9(IF 5.380)
42. Metsuyanin S, Pode-Shakked N, Schmidt-Ott KM, Keshet G, Rechavi G, Blumental D, Dekel B. **Accumulation of malignant renal stem cells is associated with epigenetic changes in normal renal progenitor genes.** *Stem Cells*. 2008 Jul; 26(7):1808-17. Epub 2008 May 8 (IF 7.531)
43. Shaklai S, Somech R, Gal-Yam EN, Deshet-Unger N, Moshitch-Moshkovitz S, Hirschberg K, Amariglio N, Simon AJ, Rechavi G. **LAP2zeta binds BAF and suppresses LAP2beta-mediated transcriptional repression.** *Eur J Cell Biol*. 2008 May; 87(5):267-78. Epub 2008 Apr 9.(IF 3.224)
44. Even-Zohar N, Jacob J, Amariglio N, Rechavi G, Potievsky O, Phillip M, Gat- Yablonski G. **Nutrition-induced catch-up growth increases hypoxia inducible factor 1alpha RNA levels in the growth plate.** *Bone*. 2008 Mar; 42(3):505-15. Epub 2007 Oct 30.(IF 3.829)
45. Balaji V, Mayrose M, Sherf O, Jacob-Hirsch J, Eichenlaub R, Iraki N, Manulis-Sasson S, Rechavi G, Barash I, Sessa G. **Tomato transcriptional changes in response to *Clavibacter michiganensis* subsp. *michiganensis* reveal a role for ethylene in disease development.** *Plant Physiol*. 2008 Apr; 146(4):1797-809. (IF 6.125)
46. Cameron D, Casey M, Press M, Lindquist D, Pienkowski T, Romieu CG, Chan S, Jagiello-Grusfeld A, Kaufman B, Crown J, Chan A, Campone M, Viens P, Davidson N, Gorbounova V, Raats JI, Skarlos D, Newstat B, Roychowdhury D, Paoletti P, Oliva C, Rubin S, Stein S, Geyer CE. **A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses.** *Breast Cancer Res Treat*. 2008 Dec; 112(3):533-43. (IF 4.671)
47. Chetrit A, Hirsh-Yechezkel G, Ben-David Y, Lubin F, Friedman E, Sadetzki S. **Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer.** *J Clin Oncol*. 2008 Jan 1; 26(1):20-5. (IF 13.598)
48. Davis FG, Malmer BS, Aldape K, Barnholtz-Sloan JS, Bondy ML, Brännström T, Bruner JM, Burger PC, Collins VP, Inskip PD, Kruchko C, McCarthy BJ, McLendon RE, Sadetzki S, Tihan T, Wrensch MR, Buffler PA. **Issues of diagnostic review in brain tumor studies: from the brain tumor epidemiology consortium.** *Cancer Epidemiol Biomarkers Prev*. 2008 Mar; 17(3):484-9. (IF 4.289)
49. El-Cheikh J, Michallet M, Nagler A, de Lavallade H, Nicolini FE, Shimoni A, Faucher C, Sobh M, Revesz D, Hardan I, Fürst S, Blaise D, Mohty M. **High response rate and improved graft-versus-host disease following bortezomib as salvage therapy after reduced intensity conditioning allogeneic stem cell transplantation for multiple myeloma.** *Haematologica*. 2008 Mar; 93(3):455-8. (IF 5.032)

50. Fronkova E, Mejstrikova E, Avigad S, Chik KW, Castillo L, Manor S, Reznickova L, Valova T, Zdrahalova K, Hrusak O, Jabali Y, Schrappe M, Conter V, Izraeli S, Li CK, Stark B, Stary J, Trka J. **Minimal residual disease (MRD) analysis in the non-MRD-based ALL IC-BFM 2002 protocol for childhood ALL: is it possible to avoid MRD testing?** *Leukemia*. 2008 May; 22(5):989-97 (IF 6.146)
51. Frumkin D, Wasserstrom A, Itzkovitz S, Harmelin A, Rechavi G, Shapiro E. **Amplification of multiple genomic loci from single cells isolated by laser micro-dissection of tissues.** *BMC Biotechnol*. 2008 Feb 20; 8:17. (IF 2.742)
52. Gold B, Kirchhoff T, Stefanov S, Lautenberger J, Viale A, Garber J, Friedman E, Narod S, Olshen AB, Gregersen P, Kosarin K, Olsh A, Bergeron J, Ellis NA, Klein RJ, Clark AG, Norton L, Dean M, Boyd J, Offit K. **Genome-wide association study provides evidence for a breast cancer risk locus at 6q22.33.** *Proc Natl Acad Sci U S A*. 2008 Mar 18; 105(11):4340-5. (IF 9.643)
53. Gratzinger D, Zhao S, Tibshirani RJ, Hsi ED, Hans CP, Pohlman B, Bast M, Avigdor A, Schiby G, Nagler A, Byrne GE Jr, Lossos IS, Natkunam Y. **Prognostic significance of VEGF, VEGF receptors, and microvessel density in diffuse large B cell lymphoma treated with anthracycline-based chemotherapy.** *Lab Invest*. 2008 Jan; 88(1):38-47. (IF 4.479)
54. Hellstrom I, Friedman E, Verch T, Yang Y, Korach J, Jaffar J, Swisher E, Zhang B, Ben-Baruch G, Tan MC, Goedegebuure P, Hellstrom KE. **Anti-mesothelin antibodies and circulating mesothelin relate to the clinical state in ovarian cancer patients.** *Cancer Epidemiol Biomarkers Prev*. 2008 Jun; 17(6):1520-6. (IF 4.289)
55. Johnston S, Trudeau M, Kaufman B, Boussen H, Blackwell K, Lorusso P, Lombardi DP, Ben Ahmed S, Citrin DL, Desilvio ML, Harris J, Westlund RE, Salazar V, Zaks TZ, Spector NL. **Phase II Study of Predictive Biomarker Profiles for Response Targeting Human Epidermal Growth Factor Receptor 2 (HER-2) in Advanced Inflammatory Breast Cancer With Lapatinib Monotherapy.** *J Clin Oncol*. 2008 Mar 1; 26(7):1066-72. (IF 13.598)
56. Koren-Michowitz M, Shimoni A, Vivante A, Trakhtenbrot L, Rechavi G, Amariglio N, Loewenthal R, Nagler A, Cohen Y. **A new MALDI-TOF-based assay for monitoring JAK2 V617F mutation level in patients undergoing allogeneic stem cell transplantation (allo SCT) for classic myeloproliferative disorders (MPD).** *Leuk Res*. 2008 Mar; 32(3):421-7. (IF 2.561)
57. Kopelman D, Inbar Y, Hanannel A, Pfeffer RM, Dogadkin O, Freundlich D, Liberman B, Catane R. **Magnetic resonance guided focused ultrasound surgery. Ablation of soft tissue at bone-muscle interface in a porcine model.** *Eur J Clin Invest*. 2008 Apr; 38(4):268-75. (IF 2.847)
58. Kochupurakkal BS, Sarig R, Fuchs O, Piestun D, Rechavi G, Givol D. **Nanog inhibits the switch of myogenic cells towards the osteogenic**

lineage. *Biochem Biophys Res Commun.* 2008 Jan 25; 365(4):846-50. (IF 2.855)

59. de Lima M, McMannis J, Gee A, Komanduri K, Couriel D, Andersson BS, Hosing C, Khouri I, Jones R, Champlin R, Karandish S, Sadeghi T, Peled T, Grynszan F, Daniely Y, Nagler A, Shpall EJ. **Transplantation of ex vivo expanded cord blood cells using the copper chelator tetraethylenepentamine: a phase I/II clinical trial.** *Bone Marrow Transplant.* 2008 May; 41(9):771-8. (IF 2.621)
60. Lo KC, Chalker J, Strehl S, Neat M, Smith O, Dastugue N, Kearney L, Izraeli S, Kempinski H, Cowell JK. **Array comparative genome hybridization analysis of acute lymphoblastic leukaemia and acute megakaryoblastic leukaemia in patients with Down syndrome.** *Br J Haematol.* 2008 Sep; 142(6):934-45. (IF 4.490)
61. Machtinger R, Inbar Y, Ben-Baruch G, Korach J, Rabinovici J. **MRgFUS for pain relief as palliative treatment in recurrent cervical carcinoma: a case report.** *Gynecol Oncol.* 2008 Jan; 108(1):241-3. (IF 2.614)
62. Marom EM, Martinez CH, Truong MT, Lei X, Sabloff BS, Munden RF, Gladish GW, Herbst RS, Morice RC, Stewart DJ, Jimenez CA, Blumenschein GR Jr, Onn A. **Tumor cavitation during therapy with antiangiogenesis agents in patients with lung cancer.** *J Thorac Oncol.* 2008 Apr; 3(4):351-7. (IF 1.429)
63. Metcalfe KA, Lubinski J, Ghadirian P, Lynch H, Kim-Sing C, Friedman E, Foulkes WD, Domchek S, Ainsworth P, Isaacs C, Tung N, Gronwald J, Cummings S, Wagner T, Manoukian S, Møller P, Weitzel J, Sun P, Narod SA. **Predictors of Contralateral Prophylactic Mastectomy in Women With a BRCA1 or BRCA2 Mutation: The Hereditary Breast Cancer Clinical Study Group.** *J Clin Oncol.* 2008 Mar 1; 26(7):1093-7. (IF 13.598)
64. Metcalfe KA, Birenbaum-Carmeli D, Lubinski J, Gronwald J, Lynch H, Moller P, Ghadirian P, Foulkes WD, Klijn J, Friedman E, Kim-Sing C, Ainsworth P, Rosen B, Domchek S, Wagner T, Tung N, Manoukian S, Couch F, Sun P, Narod SA. **International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers.** *Int J Cancer.* 2008 May 1; 122(9):2017-22. (IF 4.693)
65. Mohty M, Labopin M, Tabrizzi R, Theorin N, Fauser AA, Rambaldi A, Maertens J, Slavin S, Majolino I, Nagler A, Blaise D, Rocha V; Acute Leukemia Working Party; European Group for Blood and Marrow Transplantation. **Reduced intensity conditioning allogeneic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation.** *Haematologica.* 2008 Feb; 93(2):303-6. (IF 5.032)
66. Natkunam Y, Farinha P, Hsi ED, Hans CP, Tibshirani R, Sehn LH, Connors JM, Gratzinger D, Rosado M, Zhao S, Pohlman B, Wongchaowart N, Bast M, Avigdor A, Schiby G, Nagler A, Byrne GE, Levy R, Gascoyne RD, Lossos IS. **LMO2 protein expression predicts**

survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab. *J Clin Oncol.* 2008 Jan 20; 26(3):447-54. (IF 13.598)

67. Ostrovsky O, Korostishevsky M, Nagler A. **Reply to 'Lack of association of the heparanase gene single-nucleotide polymorphism Arg307Lys with acute lymphoblastic leukemia in patients from Northern Ireland' by Winter et al.** *Leukemia.* 2008 Feb 28. [Epub ahead of print] (IF 6.146)
68. Perlstein B, Ram Z, Daniels D, Ocherashvilli A, Roth Y, Margel S, Mardor Y. **Convection-enhanced delivery of maghemite nanoparticles: Increased efficacy and MRI monitoring.** *Neuro Oncol.* 2008 Apr; 10(2):153-61. (IF 5.806)
69. Sadetzki S, Oberman B, Mandelzweig L, Chetrit A, Ben-Tal T, Jarus-Hakak A, Duvdevani S, Cardis E, Wolf M. **Smoking and risk of parotid gland tumors: a nationwide case-control study.** *Cancer.* 2008 May 1; 112(9):1974-82. (IF 4.582)
70. Sadetzki S, Chetrit A, Jarus-Hakak A, Cardis E, Deutch Y, Duvdevani S, Zultan A, Novikov I, Freedman L, Wolf M. **Cellular phone use and risk of benign and malignant parotid gland tumors--a nationwide case-control study.** *Am J Epidemiol.* 2008 Feb 15; 167(4):457-67. (IF 5.285)
71. Schilling G, Hansen T, Shimoni A, Zabelina T, Simon-Perez JA, Gutierrez NC, Bethge W, Liebisch P, Schwerdtfeger R, Bornhäuser M, Otterstetter S, Penas EM, Dierlamm J, Ayuk F, Atanackovic D, Bacher U, Bokemeyer C, Zander A, Miguel JS, Nagler A, Kröger N. **Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myeloma.** *Leukemia.* 2008 Jun; 22(6):1250-5. (IF 6.146)
72. Shimoni A, Zwas ST, Oksman Y, Hardan I, Shem-Tov N, Rand A, Yerushalmi R, Avigdor A, Ben -Bassat I, Nagler A. **Ibritumomab tiuxetan (Zevalin) combined with reduced-intensity conditioning and allogeneic stem-cell transplantation (SCT) in patients with chemorefractory non-Hodgkin's lymphoma.** *Bone Marrow Transplant.* 2008 Feb; 41(4):355-61. (IF 2.621)
73. Simanovsky M, Berlinsky S, Sinai P, Leiba M, Nagler A, Galski H. **Phenotypic and gene expression diversity of malignant cells in human blast crisis chronic myeloid leukemia.** *Differentiation.* 2008 Oct; 76(8):908-22. (IF 2.899)
74. Spiegel A, Zcharia E, Vagima Y, Itkin T, Kalinkovich A, Dar A, Kollet O, Netzer N, Golan K, Shafat I, Ilan N, Nagler A, Vlodavsky I, Lapidot T. **Heparanase regulates retention and proliferation of primitive Sca-1+/c-Kit+/Lin- cells via modulation of the bone marrow microenvironment.** *Blood.* 2008 May 15; 111(10):4934-43. (IF 10.370)
75. Uziel O, Reshef H, Ravid A, Fabian I, Halperin D, Ram R, Bakhanashvili M, Nordenberg J, Lahav M. **Oxidative stress causes telomere damage in Fanconi anaemia cells - a possible predisposition**

for malignant transformation. *Br J Haematol.* 2008 Jul; 142(1):82-93. (IF 4.490)

76. Wolf I, Ben-Baruch N, Shapira-Frommer R, Rizel S, Goldberg H, Yaal-Hahoshen N, Klein B, Geffen DB, Kaufman B. **Association between standard clinical and pathologic characteristics and the 21-gene recurrence score in breast cancer patients: a population-based study.** *Cancer.* 2008 Feb 15; 112(4):731-6. (IF 4.632)
77. Zidan J, Hussein O, Abzah A, Tamam S, Farraj Z, Friedman E. **Oral premedication for the prevention of hypersensitivity reactions to paclitaxel.** *Med Oncol.* 2008; 25(3):274-8. (IF 1.256)
78. Zidan J, Niessen RC, Laitman Y, Rozeveld D, Hofstra RM, Friedman E. **A novel MSH2 germline mutation in a Druze HNPCC family.** *Fam Cancer.* 2008; 7(2):135-9. (IF 2.247)
79. Zippel D, Papa MZ. **The BRCA breast cancer patient: Treat the tumor or the problem?** *J Surg Oncol.* 2008 Jun 1; 97(7):561-2. (IF 2.183)
80. Markel G, Krivoy A, Rotman E, Schein O, Shrot S, Brosh-Nissimov T, Dushnitsky T, Eisenkraft A. **Medical management of toxicological mass casualty events.** *Isr Med Assoc J.* 2008 Nov;10(11):761-69.(IF 0.577)
81. Bar-Haim E, Gat O, Markel G, Cohen H, Shafferman A, Velan B. **Interrelationship between dendritic cell trafficking and Francisella tularensis dissemination following airway infection.** *PLoS Pathog.* 2008 Nov; 4(11):e1000211. (IF 1.406)
82. Makarovsky I, Markel G, Dushnitsky T, Eisenkraft A. **Ammonia--when something smells wrong.** *Isr Med Assoc J.* 2008 Jul;10(7):537-43.(IF 0.577)
83. Makarovsky I, Markel G, Dushnitsky T, Eisenkraft A. **Hydrogen fluoride--the protoplasmic poison.** *Isr Med Assoc J.* 2008 May;10(5):381-5.(IF 0.577)
84. Makarovsky I, Markel G, Dushnitsky T, Eisenkraft A. **Hydrazine--the space era agent.** *Isr Med Assoc J.* 2008 Apr; 10(4):302-6. (IF.0577)
85. Markel G, Woolfolk M, Inglehart MR. **Feeding the pipeline: academic skills training for pre dental students.** *J Dent Educ.* 2008 Jun; 72(6):653-61.(IF 1.995)
86. Arnon TI, Markel G, Bar-Ilan A, Hanna J, Fima E, Benchetrit F, Galili R, Cerwenka A, Benharroch D, Sion-Vardy N, Porgador A, Mandelboim O. **Harnessing soluble NK cell killer receptors for the generation of novel cancer immune therapy.** *PLoS ONE.* 2008 May 14 ; 3(5):e2150.
87. Makarovsky I, Markel G, Hoffman A, Schein O, Brosh-Nissimov T, Tashma Z, Dushnitsky T, Eisenkraft A. **Strychnine--a killer from the past.** *Isr Med Assoc J.* 2008 Feb;10(2):142-5.(IF 0.577)
88. Markel G, Imazio M, Brucato A, Adler Y. **Colchicine for the prevention of recurrent pericarditis.** *Isr Med Assoc J.* 2008 Jan; 10(1):69-72. (IF 0.577)

89. Izraeli S **Trisomy 21 tilts the balance.***Blood*, 2008. 112(12):4361-2. (IF 10.370)
90. Varda-Bloom N, Hodish I, Shaish A, Greenberger S, Tal R, Feder B, Roitelman J, Breitbart E, Bangio L, Barshack I, Pfeffer R, Harats D. **Specific induction of tumor neovasculature death by modified murine PPE-1 promoter armed with HSV-TK.** *Pathobiology*. 2008 ; 75(6):346-55. Epub 2008 Dec 15. (IF 1.547)
91. Liberman B, Gianfelice D, Inbar Y, Beck A, Rabin T, Shabshin N, Chander G, Hengst S, Pfeffer R, Chechick A, Hanannel A, Dogadkin O, Catane R. **Pain Palliation in Patients with Bone Metastases Using MR-Guided Focused Ultrasound Surgery: A Multicenter Study.** *Ann Surg Oncol*. 2008 Nov 11. [Epub ahead of print].(IF 3.917)
92. Giro C, Berger B, Bölke E, Ciernik IF, Duprez F, Locati L, Maillard S, Ozsahin M, Pfeffer R, Robertson AG, Langendijk JA, Budach W. **High rate of severe radiation dermatitis during radiation therapy with concurrent cetuximab in head and neck cancer: Results of a survey in EORTC institutes.** *Radiother Oncol*. 2008 Oct 30. [Epub ahead of print]. (IF 4.074)
93. Levin D, Menhel J, Alezra D, Pfeffer R. **IMRT vs. 3D noncoplanar treatment plans for maxillary sinus tumors: a new tool for quantitative evaluation.** *Med Dosim*. 2008 Winter;33(4):275-81.(IF 2.167)
94. Kundel Y, Levitt ML, Oberman B, Sadezki S, Tichler T, Symon Z, Catane R, Pfeffer R, Brenner B. **Adjuvant chemotherapy and whole abdominal irradiation for gastric carcinoma.** *Tumori*. 2008 Jul-Aug;94(4):469-73.(IF 0.597)
95. Mendlovic S, Symon Z, Kundel Y, Rabin T, Catane R, Pfeffer R. **[Three-dimensional conformal radiation therapy concurrent with full dose Gemcitabine for locally advanced inoperable pancreatic cancer]** *Harefuah*. 2008 May; 147(5):384-7, 480.
96. Kopelman D, Inbar Y, Hanannel A, Pfeffer RM, Dogadkin O, Freundlich D, Liberman B, Catane R. **Magnetic resonance guided focused ultrasound surgery. Ablation of soft tissue at bone-muscle interface in a porcine model.** *Eur J Clin Invest*. 2008 Apr;38(4):268-75.(IF 2.701)
97. Paluch-Shimon S, Wolf I, Goldberg H, Evron E, Papa MZ, Shabtai M, Barsuk D, Yosepovich A, Modiano T, Catane R, Kaufman B. **High efficacy of pre-operative trastuzumab combined with paclitaxel following doxorubicin & cyclophosphamide in operable breast cancer***Acta Oncol*. 2008; 47(8):1564-9. (IF 2.274)
98. Willhauck MJ, Sharif Samani BR, Klutzn K, Cengic N, Wolf I, Mohr L, Geissler M, Senekowitsch-Schmidtke R, Göke B, Morris JC, Spitzweg C. **Alpha-fetoprotein promoter-targeted sodium iodide symporter gene therapy of hepatocellular carcinoma.** *Gene Ther*. 2008 Feb; 15(3):214-23. Epub 2007 Nov 8. (IF 4.812)
99. Maier-Hein L, Tekbas A, Franz AM, Tetzlaff R, Müller SA, Pianka F, Wolf I, Kauczor HU, Schmied BM, Meinzer HP. **On combining internal**

and external fiducials for liver motion compensation. *Comput Aided Surg.* 2008 Nov; 13(6):369-76.

100. Pfeiffer A, Kunkel T, Hiltbrunner A, Neuhaus G, Wolf I, Speth V, Adam E, Nagy F, Schäfer E. **A cell-free system for light-dependent nuclear import of phytochrome.** *Plant J.* 2008 Nov 24. [Epub ahead of print]. (IF 6.751)
101. Wolf I, Levanon-Cohen S, Bose S, Ligumsky H, Sredni B, Kanety H, Kuro-o M, Karlan B, Kaufman B, Koeffler HP, Rubinek T. **Klotho: a tumor suppressor and a modulator of the IGF-1 and FGF pathways in human breast cancer.** *Oncogene.* 2008 Nov 27; 27(56):7094-105. Epub 2008 Sep 1.(IF 6.440)
102. Wakimoto N, Wolf I, Yin D, O'Kelly J, Akagi T, Abramovitz L, Black KL, Tai HH, Koeffler HP. **Nonsteroidal anti-inflammatory drugs suppress glioma via 15-hydroxyprostaglandin dehydrogenase.** *Cancer Res.* 2008 Sep 1; 68(17):6978-86. (IF 6.177)
103. Wolf I, Shapira A, Giniger R, Miller Y, Gerber RB, Cheshnovsky O. **Critical size for intracuster proton transfer from water to an anion.** *Angew Chem Int Ed Engl.* 2008; 47(33):6272-4. (IF 10.031)
104. Maier-Hein L, Müller SA, Pianka F, Wörz S, Müller-Stich BP, Seitel A, Rohr K, Meinzer HP, Schmied BM, Wolf I. **Respiratory motion compensation for CT-guided interventions in the liver.** *Comput Aided Surg.* 2008 May; 13(3):125-38.
105. Willhauck MJ, Samani BR, Wolf I, Senekowitsch-Schmidtke R, Stark HJ, Meyer GJ, Knapp WH, Göke B, Morris JC, Spitzweg C. **The potential of 211Astatine for NIS-mediated radionuclide therapy in prostate cancer.** *Eur J Nucl Med Mol Imaging.* 2008 Jul; 35(7):1272-81. (IF 4.101)
106. Dotan ZA, Dotan A, Ramon J, Avivi L. **Aberrant allele-specific replication, independent of parental origin, in blood cells of cancer patients.** *BMC Cancer.* 2008 Dec 25; 8(1):390. (IF 2.709)
107. Nadu A, Kleinmann N, Laufer M, Dotan Z, Winkler H, Ramon J. **Laparoscopic partial nephrectomy for central tumors: analysis of perioperative outcomes and complications***J Urol.* 2009 Jan; 181(1):42-7; discussion 47. (IF 4.053)
108. Fridman E, Skarda J, Pinthus JH, Ramon J, Mor Y. **Expression of multidrug resistance-related protein (MRP-1), lung resistance-related protein (LRP) and topoisomerase-II (TOPO-II) in Wilms' tumor: immunohistochemical study using TMA methodology.** *Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub.* 2008 Jun; 152(1):47-51.
109. Cortesi M, Fridman E, Volkov A, Shilstein SSh, Chechik R, Breskin A, Vartsky D, Kleinman N, Kogan G, Moriel E, Gladyshev V, Huszar M, Ramon J, Raviv G. **Clinical assessment of the cancer diagnostic value of prostatic zinc: a comprehensive needle-biopsy study.** *Prostate.* 2008 Jun 15; 68(9):994-1006. (IF 3.674)

110. Arien-Zakay H, Lecht S, Bercu MM, Tabakman R, Kohen R, Galski H, Nagler A, Lazarovici P. **Neuroprotection by cord blood neural progenitors involves antioxidants, neurotrophic and angiogenic factors.** *Exp Neurol.* 2008 Nov 25. [Epub ahead of print. (IF 3.982)
111. Benjamini O, Koren-Michowitz M, Amariglio N, Kroger N, Nagler A, Shimoni A. **Relapse of postpolycythemia myelofibrosis after allogeneic stem cell transplantation in a polycythemic phase: successful treatment with donor lymphocyte infusion directed by quantitative PCR test for V617F-JAK2 mutation.** *Leukemia.* 2008 Oct; 22(10):1961-3. (IF 6.146)
112. Turgeman T, Hagai Y, Huebner K, Jassal DS, Anderson JE, Genin O, Nagler A, Halevy O, Pines M. **Prevention of muscle fibrosis and improvement in muscle performance in the mdx mouse by halofuginone.** *Neuromuscul Disord.* 2008 Nov; 18(11):857-68.
113. Hartmann TN, Grabovsky V, Pasvolsky R, Shulman Z, Buss EC, Spiegel A, Nagler A, Lapidot T, Thelen M, Alon R. **A crosstalk between intracellular CXCR7 and CXCR4 involved in rapid CXCL12-triggered integrin activation but not in chemokine-triggered motility of human T lymphocytes and CD34+ cells.** *J Leukoc Biol.* 2008 Oct; 84(4):1130-40. (IF 4.128)
114. Ayuk F, Perez-Simon JA, Shimoni A, Sureda A, Zabelina T, Schwerdtfeger R, Martino R, Sayer HG, Alegre A, Lahuerta JJ, Atanackovic D, Wolschke C, Nagler A, Zander AR, San Miguel JF, Kröger N. **Clinical impact of human Jurkat T-cell-line-derived antithymocyte globulin in multiple myeloma patients undergoing allogeneic stem cell transplantation** *Haematologica.* 2008 Sep; 93(9):1343-50.(IF 5.516)
115. Ciceri F, Labopin M, Aversa F, Rowe JM, Bunjes D, Lewalle P, Nagler A, Di Bartolomeo P, Lacerda JF, Lupo Stanghellini MT, Polge E, Frasson F, Martelli MF, Rocha V; Acute Leukemia Working Party (ALWP) of European Blood and Marrow Transplant (EBMT) Group. **A survey of fully haploidentical hematopoietic stem cell transplantation in adults with high-risk acute leukemia: a risk factor analysis of outcomes for patients in remission at transplantation.** *Blood.* 2008 Nov 1; 112(9):3574-81. (IF 10.370)
116. Shimoni A, Leiba M, Schleuning M, Martineau G, Renaud M, Koren-Michowitz M, Ribakowski E, le Coutre P, Arnold R, Guilhot F, Nagler A. **Prior treatment with the tyrosine kinase inhibitors dasatinib and nilotinib allows stem cell transplantation (SCT) in a less advanced disease phase and does not increase SCT Toxicity in patients with chronic myelogenous leukemia and philadelphia positive acute lymphoblastic leukemia.** *Leukemia.* 2009 Jan; 23(1):190-4. (IF 6.146)
117. Sonneveld P, Hajek R, Nagler A, Spencer A, Bladé J, Robak T, Zhuang SH, Harousseau JL, Orlowski RZ; DOXIL-MMY-3001 Study Investigators **Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory**

multiple myeloma who received prior thalidomide lenalidomide therapy. *Cancer*. 2008 Apr 1; 112(7):1529-37.(IF 4.632)

118. Besser MJ, Shapira R, Treves AJ, Zippel D, Itzhaki O, Schallach E, Kubi A, Shalmon B, Hardan I, Catane R, Segal E, Markel G, Apter S, Ben-Nun A, Kuchuk I, Shimoni A, Nagler A, Schachter J. **Entitled "Minimally – cultured or selected autologous tumor infiltrating lymphocytes following a lymphodepleting chemotherapy Regimen in Metastatic Melanoma Patients"** *Immunotherapy* 2009 Jan In Press.
119. Itzhaki O, Skutelsky E, Kaptzan T, Siegal A, Sinai J, Schiby G, Michowitz M, Huszar M, Leibovici J. **Decreased DNA ploidy may constitute a mechanism of the reduced malignant behavior of B16 melanoma in aged mice.** *Exp Gerontol*. 2008 Mar; 43(3):164-75. (IF 2.871)
120. Leibovici J, Itzhaki O, Kaptzan T, Skutelsky E, Sinai J, Michowitz M, Asfur R, Siegal A, Huszar M, Schiby G. **Designing ageing conditions in tumour microenvironment-A new possible modality for cancer treatment .** *Mech Ageing Dev*. 2009; 130(1-2):76-85.
121. Goldberg L, Ocherashvilli A, Daniels D, Last D, Cohen ZR, Tamar G, Kloog Y, Mardor Y. **Salirasib (farnesyl thiosalicylic acid) for brain tumor treatment: a convection-enhanced drug delivery study in rats.** *Mol Cancer Ther*. 2008 Nov; 7(11):3609-16. (IF 4.800)
122. Sadetzki S, Zach L, Chetrit A, Nass D, Hoffmann C, Ram Z, Zaaroor M, Umansky F, Rappaport ZH, Cohen A, Wald U, Rothman S, Hadani M. **Epidemiology of gliomas in Israel: a nationwide study.** *Neuroepidemiology*. 2008; 31(4):264-9. (IF 2.203)
123. Chetrit A, Hirsh-Yechezkel G, Ben-David Y, Lubin F, Friedman E, Sadetzki S. **Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer.** *J Clin Oncol*. 2008 Jan 1; 26(1):20-5. (IF 15.848)
124. Efrati O, Toren A, Duskin H, Modan-Moses D, Bielorai B, Goldstein G, Churi C, Vilozni D. **Pulmonary function studies in children treated by chemoradiotherapy and stem cell transplantation.** *Pediatr Blood Cancer*. 2008 Nov;51(5):684-8 (IF 2.164)
125. Keinan-Boker L, Lerner-Geva L, Kaufman B, Meirow D. **Pregnancy-associated breast cancer.** *Isr Med Assoc J*. 2008 Oct;10(10):722-7 (IF 0.577)